{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-24-000023","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.573816+00:00","generated_at":"2026-06-03T00:37:46.035283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B","bullets":["GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.","Spikevax product sales fell 91% YoY to $167M; $100M U.S., $67M international.","Reaffirms 2024 product sales ~$4B; expects ~$0.3B net sales in H1 2024.","Cash and investments $12.2B at March 31, down from $13.3B at year-end 2023.","RSV vaccine launch targeted for fall 2024; flu vaccine filing expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-24-000023","json":"https://secwatch.observer/filing/0001682852-24-000023.json","markdown":"https://secwatch.observer/filing/0001682852-24-000023.md","text":"https://secwatch.observer/filing/0001682852-24-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/0001682852-24-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/mrna-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:37:46.035283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50e925cd5e349fd143caf99dcede4f426670bc56","claim":"Moderna, Inc. reported the first quarter ended March 31, 2024 results: revenue $167 million, net income GAAP net loss of $1.2 billion, EPS GAAP diluted EPS of $(3.07). Guidance reaffirmed.","evidence_excerpt":"Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million , GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/0001682852-24-000023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$167 million"},{"label":"Net income","value":"GAAP net loss of $1.2 billion"},{"label":"EPS","value":"GAAP diluted EPS of $(3.07)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}